Sabatolimab binds to the surface of T-cells, releasing the breaks that the tumor applied to the immune system. (HMA) or hypomethylating agents act by inducing DNA hypomethylation and corresponding alterations in gene expression.
Patients with higher-risk MDS and AML need treatment options that provide stable responses with sustained clinical benefit and favorable safety/tolerability. Sabatolimab in combination with a hypomethylating agent was cited comprehensively in MDS sessions at ASH 2022, in this article, the highlights of the clinical trial will be presented.
TIM-3 is an immune regulator expressed on immune cells and myeloid leukemic progenitors but not on normal hematopoietic stem cells. Sabatolimab + HMA (hypomethylating agent) has been shown to deliver promising durable responses in a phase Ib study in patients with vHR/HR-MDS (very high-risk/high-risk myelodysplastic syndrome) or newly diagnosed AML (acute myeloid leukemia) (Wei et al. EHA 2021; NCT03066648).
The primary objective was to evaluate safety and tolerability. A secondary objective, preliminary efficacy, was assessed with overall response rate, duration of response, and progression-free survival endpoints. The proportion of patients who had a possible immune-mediated adverse event was evaluated among patients who achieved remission compared with those who did not.
As of the 15 Jun 2021 data cutoff, 53 patients with very high risk/high-risk MDS and 48 with ND-AML were treated with sabatolimab + HMA. The combination was safe and well tolerated, with the most common adverse effects similar to HMA alone, consisting of thrombocytopenia, neutropenia, anemia, and febrile neutropenia. No pt with vHR/HR-MDS and only 3 with ND-AML discontinued treatment due to an adverse effect regardless of relationship to treatment.
In very high-risk/ high risk MDS, 24.5% of patients had improvement allowing them to undergo HSCT (hematopoietic stem cell transplantation).
Long-lasting responses were also observed in patients with adverse-risk mutations, including TP53 mutations in patients with very high risk/high-risk MDS and at least 1 ELN (European LeukemiaNet) adverse-risk mutation (TP53/RUNX1/ASXL1) in patients with newly diagnosed AML.
Sabatolimab + Hypomethylating agents was safe and well tolerated and demonstrated stable clinical responses in patients with very high risk/high-risk-MDS and newly diagnosed-AML. Responses were also durable in patients with adverse-risk mutations.
References:
Sabatolimab binds to the surface of T-cells, releasing the breaks that the tumor applied to the immune system. (HMA) or hypomethylating agents act by inducing DNA hypomethylation and corresponding alterations in gene expression.
Patients with higher-risk MDS and AML need treatment options that provide stable responses with sustained clinical benefit and favorable safety/tolerability. Sabatolimab in combination with a hypomethylating agent was cited comprehensively in MDS sessions at ASH 2022, in this article, the highlights of the clinical trial will be presented.
TIM-3 is an immune regulator expressed on immune cells and myeloid leukemic progenitors but not on normal hematopoietic stem cells. Sabatolimab + HMA (hypomethylating agent) has been shown to deliver promising durable responses in a phase Ib study in patients with vHR/HR-MDS (very high-risk/high-risk myelodysplastic syndrome) or newly diagnosed AML (acute myeloid leukemia) (Wei et al. EHA 2021; NCT03066648).
The primary objective was to evaluate safety and tolerability. A secondary objective, preliminary efficacy, was assessed with overall response rate, duration of response, and progression-free survival endpoints. The proportion of patients who had a possible immune-mediated adverse event was evaluated among patients who achieved remission compared with those who did not.
As of the 15 Jun 2021 data cutoff, 53 patients with very high risk/high-risk MDS and 48 with ND-AML were treated with sabatolimab + HMA. The combination was safe and well tolerated, with the most common adverse effects similar to HMA alone, consisting of thrombocytopenia, neutropenia, anemia, and febrile neutropenia. No pt with vHR/HR-MDS and only 3 with ND-AML discontinued treatment due to an adverse effect regardless of relationship to treatment.
In very high-risk/ high risk MDS, 24.5% of patients had improvement allowing them to undergo HSCT (hematopoietic stem cell transplantation).
Long-lasting responses were also observed in patients with adverse-risk mutations, including TP53 mutations in patients with very high risk/high-risk MDS and at least 1 ELN (European LeukemiaNet) adverse-risk mutation (TP53/RUNX1/ASXL1) in patients with newly diagnosed AML.
Sabatolimab + Hypomethylating agents was safe and well tolerated and demonstrated stable clinical responses in patients with very high risk/high-risk-MDS and newly diagnosed-AML. Responses were also durable in patients with adverse-risk mutations.
References:
about the author
Jimena Vicencio
Jimena is an International Medical Graduate and a member of the HealthTree Writing team. She has a passion for languages and is currently learning Japanese. In her free time, she loves playing with her cats. Jimena is also pursuing a bachelor's degree in journalism.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.